BRIEF-Merck Enters Exclusive Global License Deal With Scibrunch Therapeutics For SPR2015
Reuters2026/09/28 11:07Sept 28 (Reuters) - Merck & Co Inc MRK.N:
SAYS MERCK ENTERS EXCLUSIVE GLOBAL LICENSE DEAL WITH SCIBRUNCH THERAPEUTICS FOR INVESTIGATIONAL ORAL KRAS G12D (ON) INHIBITOR SPR2015
Further company coverage: MRK.N
(Reporting by Beijing Newsroom)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Tom Lee Says a VIX Signal Points to a Stock Market Bottom
Is AI an engine or a killer? Morgan Stanley provides answers with data: productivity soars, but nearly 90% of the benefits are taken by 12 industries
Morgan Stanley stated that the productivity dividends from AI are concentrated in 12 highly exposed industries, with growth rates reaching twice the twenty-year average. For the first time, signs of job replacement have emerged.
Crypto prices
More
